Featured Research

from universities, journals, and other organizations

Major South African trial did not improve tuberculosis control in gold mines

Date:
January 22, 2014
Source:
London School of Hygiene & Tropical Medicine
Summary:
A major trial aiming to cut the rate of tuberculosis among South Africa's gold miners did not reduce the number of cases or deaths from the disease, according to a study.

A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease, according to a study published in the New England Journal of Medicine.

Researchers from the London School of Hygiene & Tropical Medicine say that the results demonstrate the scale of the TB problem in South African gold mines, and highlight the need for a "combination prevention" approach to improve TB control.

The TB epidemic in South Africa's gold mines worsened with the advent of the HIV epidemic in the 1990s. In 2008, around 3% of miners started TB treatment each year.

The Thibela TB study of 78,744 miners in 15 gold mines from 2006 to 2011 looked at the effectiveness of screening and treating active TB, and providing preventive therapy to the entire workforce with the aim of interrupting TB transmission.

27,126 miners in eight gold mines were screened for TB. Miners found to have active TB disease were given TB treatment, and all other miners were offered a nine-month course of isoniazid preventive therapy (a low-cost medication that prevents latent tuberculosis infection from progressing to clinically apparent disease). In the other seven mines, the mine TB control programmes continued their usual practice, which included access to free TB diagnosis and treatment services, and active screening for TB at least once a year, with isoniazid preventive therapy included as part of HIV care.

Although isoniazid preventative therapy was found to be safe and effective in preventing TB among people who took it, the effect wore off very rapidly once the treatment stopped. 12 months after the end of the intervention, researchers did not find any difference in the number of cases of TB between the workers in the mines where mass TB screening and preventive therapy was offered, compared to mines continuing standard practice.

Lead London School of Hygiene & Tropical Medicine investigator Alison Grant, Professor of International Health, said: "HIV, exposure to silica dust in the mines and close working and living conditions predispose South African gold miners to TB. As conventional control methods were not working, we investigated a radical approach to TB control. Our study shows that isoniazid preventive therapy works while people take it, but, in this setting, the effect was not enough to improve overall TB control. The findings highlight the scale of the problem of TB in these mines.

"Our data suggests that to control TB in South African gold mines, we need a "combination prevention" approach with better tests to find TB, prompt treatment for those found to have active TB, increased coverage of HIV treatment and effective TB preventive therapy regimens. Continuous isoniazid preventative therapy should be considered for miners at highest risk of TB infection, such as those with HIV. "


Story Source:

The above story is based on materials provided by London School of Hygiene & Tropical Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gavin J. Churchyard, Katherine L. Fielding, James J. Lewis, Leonie Coetzee, Elizabeth L. Corbett, Peter Godfrey-Faussett, Richard J. Hayes, Richard E. Chaisson, Alison D. Grant. A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control. New England Journal of Medicine, 2014; 370 (4): 301 DOI: 10.1056/NEJMoa1214289

Cite This Page:

London School of Hygiene & Tropical Medicine. "Major South African trial did not improve tuberculosis control in gold mines." ScienceDaily. ScienceDaily, 22 January 2014. <www.sciencedaily.com/releases/2014/01/140122202219.htm>.
London School of Hygiene & Tropical Medicine. (2014, January 22). Major South African trial did not improve tuberculosis control in gold mines. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/01/140122202219.htm
London School of Hygiene & Tropical Medicine. "Major South African trial did not improve tuberculosis control in gold mines." ScienceDaily. www.sciencedaily.com/releases/2014/01/140122202219.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins